Lecture
This lecture covers the development of the first AAV vector, AAV2, and the challenges posed by pre-existing antibodies in adults, as well as the diversity of AAV serotypes and variants. The lecturer explains how different AAV serotypes target specific organs and cell types, allowing for tailored applications. AAV vectors have a small capsid size, limiting the size of genetic material that can be inserted, but their stability and resistance to various conditions make them ideal for gene therapy applications.